On May 6, 2024 Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, reported that its abstract, In Vivo Generation of αCD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears Advanced NALM-6 Tumor without Noticeable Toxicity, has been selected for an oral presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held May 7-11, 2024, in Baltimore, Maryland (Press release, Vyriad, MAY 6, 2024, View Source;cell-therapy-annual-meeting-302137235.html [SID1234642699]). Vyriad’s presentation will discuss progress in developing its highly targeted, efficient, serum-stable and durable lentiviral vector technology to deliver genetic payloads directly and specifically to CD3+ T cells in vivo.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Title: In Vivo Generation of αCD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears Advanced NALM-6 Tumor without Noticeable Toxicity

Session Name: CAR T-cell Therapies

Presentation Date/Time: Thursday, May 9, at 5:15 p.m. EST

Presenting Speaker: Karina Krotova, Ph.D., Principal Scientist, Imanis Life Sciences

Full abstracts are available for online viewing via the ASGCT (Free ASGCT Whitepaper) Annual Meeting website at View Source